Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in leber congenital amaurosis

被引:122
作者
Jacobson, Samuel G.
Boye, Sanford L.
Aleman, Tomas S.
Conlon, Thomas J.
Zeiss, Caroline J.
Roman, Alejandro J.
Cideciyan, Artur V.
Schwartz, Sharon B.
Komaromy, Andras M.
Doobrajh, Michelle
Cheung, Andy Y.
Sumaroka, Alexander
Pearce-Kelling, Susan E.
Aguirre, Gustavo D.
Kaushal, Shalesh
Maguire, Albert M.
Flotte, Terence R.
Hauswirth, William W.
机构
[1] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA
[2] Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA
[3] Univ Florida, Powell Gene Therapy Ctr, Genet Inst, Gainesville, FL 32610 USA
[4] Univ Florida, Dept Pediat, Gainesville, FL 32610 USA
[5] Univ Florida, Dept Pathol, Gainesville, FL 32610 USA
[6] Univ Florida, Dept Pharmaceut, Gainesville, FL 32610 USA
[7] Yale Univ, Sch Med, Sect Comparat Med, New Haven, CT 06520 USA
[8] Univ Penn, Sch Vet Med, Sect Med Genet, Philadelphia, PA 19104 USA
[9] Cornell Univ, James A Baker Inst Anim Hlth, Ithaca, NY 14853 USA
关键词
D O I
10.1089/hum.2006.17.845
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Leber congenital amaurosis (LCA) is a molecularly heterogeneous disease group that leads to blindness. LCA caused by RPE65 mutations has been studied in animal models and vision has been restored by subretinal delivery of AAV-RPE65 vector. Human ocular gene transfer trials are being considered. Our safety studies of subretinal AAV-2/2.RPE65 in RPE65-mutant dogs showed evidence of modest photoreceptor loss in the injection region in some animals at higher vector doses. We now test the hypothesis that there can be vector-related toxicity to the normal monkey, with its human-like retina. Good Laboratory Practice safety studies following single intraocular injections of AAV-2/2.RPE65 in normal cynomolgus monkeys were performed for 1-week and 3-month durations. Systemic toxicity was not identified. Ocular-specific studies included clinical examinations, electroretinography, and retinal histopathology. Signs of ocular inflammation postinjection had almost disappeared by 1 week. At 3 months, electroretinography in vector-injected eyes was no different than in vehicle-injected control eyes or compared with presurgical recordings. Healed sites of retinal perforation from subretinal injections were noted clinically and by histopathology. Foveal architecture in subretinally injected eyes, vector or vehicle, could be abnormal. Morphometry of central retina showed no photoreceptor layer thickness abnormalities occurring in a dose-dependent manner. Vector sequences were present in the injected retina, vitreous, and optic nerve at 1 week but not consistently in the brain. At 3 months, there were no vector sequences in optic nerve and brain. The results allow for consideration of an upper range for no observed adverse effect level in future human trials of subretinal AAV-2/2.RPE65. The potential value of foveal treatment for LCA and other retinal degenerations warrants further research into how to achieve gene transfer without retinal injury from surgical detachment of the retina.
引用
收藏
页码:845 / 858
页数:14
相关论文
共 43 条
[1]   Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness [J].
Acland, GM ;
Aguirre, GD ;
Bennett, J ;
Aleman, TS ;
Cideciyan, AV ;
Bennicelli, J ;
Dejneka, NS ;
Pearce-Kelling, SE ;
Maguire, AM ;
Palczewski, K ;
Hauswirth, WW ;
Jacobson, SG .
MOLECULAR THERAPY, 2005, 12 (06) :1072-1082
[2]   Gene therapy restores vision in a canine model of childhood blindness [J].
Acland, GM ;
Aguirre, GD ;
Ray, J ;
Zhang, Q ;
Aleman, TS ;
Cideciyan, AV ;
Pearce-Kelling, SE ;
Anand, V ;
Zeng, Y ;
Maguire, AM ;
Jacobson, SG ;
Hauswirth, WW ;
Bennett, J .
NATURE GENETICS, 2001, 28 (01) :92-95
[3]   Adeno-associated viral vectors for retinal gene transfer and treatment of retinal diseases [J].
Auricchio, A ;
Rolling, F .
CURRENT GENE THERAPY, 2005, 5 (03) :339-348
[4]   Pharmacological and rAAV gene therapy rescue of visual functions in a blind mouse model of leber congenital amaurosis [J].
Batten, ML ;
Imanishi, Y ;
Tu, DC ;
Doan, T ;
Zhu, L ;
Pang, JJ ;
Glushakova, L ;
Moise, AR ;
Baehr, W ;
Van Gelder, RN ;
Hauswirth, WW ;
Rieke, F ;
Palczewski, K .
PLOS MEDICINE, 2005, 2 (11) :1177-1189
[5]   Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina [J].
Bennett, J ;
Maguire, AM ;
Cideciyan, AV ;
Schnell, M ;
Glover, E ;
Anand, V ;
Aleman, TS ;
Chirmule, N ;
Gupta, AR ;
Huang, YJ ;
Gao, GP ;
Nyberg, WC ;
Tazelaar, J ;
Hughes, J ;
Wilson, JM ;
Jacobson, SG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) :9920-9925
[6]   Preclinical. gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors [J].
Couto, LB .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2004, 30 (02) :161-171
[7]   Molecular genetics of Leber congenital amaurosis [J].
Cremers, FPM ;
van den Hurk, JAJM ;
den Hollander, AI .
HUMAN MOLECULAR GENETICS, 2002, 11 (10) :1169-1176
[8]   HUMAN PHOTORECEPTOR TOPOGRAPHY [J].
CURCIO, CA ;
SLOAN, KR ;
KALINA, RE ;
HENDRICKSON, AE .
JOURNAL OF COMPARATIVE NEUROLOGY, 1990, 292 (04) :497-523
[9]   In utero gene therapy rescues vision in a murine model of congenital blindness [J].
Dejneka, NS ;
Surace, EM ;
Aleman, TS ;
Cideciyan, AV ;
Lyubarsky, A ;
Savchenko, A ;
Redmond, TM ;
Tang, WX ;
Wei, ZY ;
Rex, TS ;
Glover, E ;
Maguire, AM ;
Pugh, EN ;
Jacobson, SG ;
Bennett, J .
MOLECULAR THERAPY, 2004, 9 (02) :182-188
[10]   Adeno-associated virus-vectored gene therapy for retinal disease [J].
Dinculescu, A ;
Glushakova, L ;
Min, SH ;
Hauswirth, WW .
HUMAN GENE THERAPY, 2005, 16 (06) :649-663